知镜 Cognispect · 医学文献与研究工作台

Pulmonary Arterial Hypertension-Targeted Therapy for Pulmonary Hypertension Associated With Left Heart Disease: Bayesian and Frequentist Meta-Analysis of Randomized Controlled Trials.

Kiyohara Y, Sakai T, Freeman LM, Katzianer D, Siuba MT, Chaisson N, Correa A, Trivieri MG, Tang WHW, Yano Y, Naito T, Miyashita S.
The American journal of cardiology · 2026-08-04 · PMID 42551818

文献摘要

Pulmonary hypertension associated with left heart disease (PH-LHD) is the most prevalent form of pulmonary hypertension. Despite the recent advances in medications for pulmonary artery hypertension (PAH), it remains unclear whether PAH-targeted therapy is effective in patients with PH-LHD. We searched PubMed and EMBASE through October 1, 2025 for randomized controlled trials comparing PAH-targeted therapy (i.e., endothelin receptor antagonist and phosphodiesterase-5 inhibitor) and placebo for patients with PH-LHD. The primary outcome was all-cause mortality, and secondary outcomes included adverse events and heart failure hospitalization. First, we performed Bayesian random-effects meta-analysis with weakly informative priors, using study-specific effect estimates and standard errors, with subgroup analysis for heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Additionally, we conducted frequentist meta-analysis. We identified 8 randomized controlled trials in a total of 775 patients. In Bayesian meta-analysis, we estimated the probability that PAH-targeted therapy increased all-cause mortality at 79.9% (risk ratio [RR]: 1.55; 95% credible interval [0.51 to 4.36]) and adverse events at 94.8% (RR: 1.13; 95% credible interval [0.96 to 1.38]), compared with placebo. In the subgroup analysis, no material difference was observed between heart failure with reduced ejection fraction and HFpEF, with HFpEF demonstrating a 62% probability of a smaller risk increase. In frequentist meta-analysis, there was no significant difference in all-cause mortality, while PAH-targeted therapy was associated with significantly increased adverse events, compared with placebo (RR: 1.15; 95% CI 1.04 to 1.28). In conclusion, PAH-targeted therapy was associated with a moderate probability of increased mortality and a high probability of increased adverse events.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。